Emily Pistilli’s practice centers on complex civil litigation, including the representation of pharmaceutical manufacturers in multi-jurisdictional products liability litigation. She has served on the national defense counsel teams for some of the largest pharmaceutical proceedings in the country. Emily also has extensive experience representing healthcare companies as settlement counsel, focusing on global resolution strategies for mass tort litigation. She has represented corporate clients in a variety of other matters, including executive compensation and commercial contract disputes.
Emily grew up in Rhode Island, and received a B.A. magna cum laude from the University of Pennsylvania in 1999. She received her J.D., cum laude, from the Harvard Law School in 2005 and was an editor of the Harvard Law Review. She clerked for Judge Ellen Segal Huvelle of the United States District Court for the District of Columbia from 2006 to 2008.
- Representation of Merck in Incretin-Based Therapies cases in federal and California state coordinated proceedings.
- Representation of Takeda in connection with negotiation and implementation of the Actos Resolution Program, a private settlement program established for the purpose of resolving personal injury claims relating to the anti-diabetic medication Actos.
- Representation of AstraZeneca in the MDL litigation involving Seroquel, a second-generation antipsychotic medication.
- Settlement counsel for Merck in multi-district litigation involving Merck’s hormonal contraceptive product, NuvaRing.
- Representation of Merck in the Vioxx MDL litigation, including defense of related individual personal injury actions.